Drug intelligence / Profile preview

VL001

Development stage: Unknown
Lead developer: PulmoSIM Therapeutics
Modality: Small Molecules

Overview

VL001 is an investigational drug candidate currently in Phase 1 clinical development for the treatment of oncology. Developed by PulmoSIM Therapeutics, a subsidiary of VeriSIM Life, the asset was identified using the BIOiSIM AI-driven drug discovery and development platform. PulmoSIM Therapeutics specializes in the repurposing of existing therapeutic compounds to address unmet needs in respiratory and oncological diseases. While VL001 is listed in the company's pipeline as a Phase 1 asset for cancer, specific details regarding its chemical structure, molecular target, and mechanism of action have not been publicly disclosed by the developer as of early 2024.

Beyond the preview

Go deeper on VL001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VL001.

Explore the full profile